MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.
More...
Linear Mode
